Vrtik mission is to conduct effective support for public policies that encourage discovery of necessary new medicines for patients by pharmaceutical and biotechnology analysis firms. To accomplish this mission, Vrtik is devoted to achieving these goals in Asian country and world:
Broad patient access to safe and effective medicines through a free market, while not value controls
Strong ma
terial possession incentives
And clear, effective regulation and a free flow of data to patients. Who We Are
Our Pharmaceutical analysis and makers represents innovative bio pharmaceutical analysis and discovery firms. Vrtik is dedicated to advancing public policies in Asian country and round the world that support innovative medical analysis yield progress for patients nowadays and supply hope for the treatments and cures of tomorrow. What we tend to Believe
We believe a vivacious bio pharmaceutical analysis business is important to patients and world health This requires:
A business setting that conjures up and rewards investment in analysis and development, whereas recognizing the distinctive risks and prices of our industry’s marketplace
A thriving and cooperative scientific scheme that advances information and innovation
A modern, clear regulative system that evolves with the science to bring safe and effective medicines to patients quickly
A correct valuation for innovative medicines. Vrtik History
Vrtik was shaped to represent India’s bio pharmaceutical analysis firms and ask for essential alignment between public policy and medical analysis to deal with patient wants. Our offices in leading bio pharmaceutical analysis communities, Vrtik advocates in Asian country and round the world on public policy problems important to the invention and development of innovative medicines. These priorities embody the inflated complexity and risk of the analysis and development method, continued would like for investment in R&D, broad access to and acceptable use of medicines, inflated worth for today’s patients, and also the continued importance of robust material possession incentives for brand spanking new medicines.
